

March 13, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,
The Manager – Listing
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

To,
Glenmark Life Sciences Limited
Plot No 170-172
Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213


Dear Sir/Madam,

Sub: Disclosure under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011 in connection with release of encumbrance of equity shares of Glenmark Life Sciences Limited ("GLS")

Dear Sir / Ma'am,

Pursuant to Regulation 31(2) read with Regulation 28(3) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, as amended ("Takeover Code"), as prescribed pursuant to the Master Circular for Takeover Code, bearing reference no. SEBI/HO/CFD/PoD-1/P/CIR/2023/31, dated February 16, 2023, please find attached disclosure in relation to the release of encumbrance of equity shares of GLS in Annexure A.

For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary and Compliance Officer
Encl.: As above



Annexure A

Disclosure by the Promoter(s) to the stock exchange and to the Target Company for encumbrance of shares / invocation of encumbrance / release of encumbrance, in terms of Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company(TC)	Glenmark Life Sciences Limited ("GLS")				
Names of the stock exchanges where the shares of the target company are listed	BSE Limited and National Stock Exchange of India Limited				
Date of reporting	March 13, 2024				
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked	Glenmark Pharmaceuticals Limited				
Details of the creation of encumbrance: N.A.					
Name of the promoter(s) or PACs with him*	Promoter holding in the target company (1)	Promoter holding already encumbered (2)	Details of events pertaining to encumbrance (3)	Post event holding of encumbered shares {creation [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}	



	Number	% of total share capital	Number	% of total share capital	Type of event (creation / release / invocation)	Date of creation / release / invocation of encumbrance	Type of encumbrance (pledge / lien / non disposal undertaking / others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favour shares encumbered	Number	% of total share capital
Glenmark Pharmaceuticals Limited	34,115,006	27.84%	34,115,006*	27.84%*	Release	March 12, 2024	Others	Lock-in as promoter's contribution pursuant to SEBI ICDR Regulations	24,505,435	20%	N.A.	9,609,571	7.84%
Glenn Mario Saldanha	7,800	0.01%	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

* Out of the total of 34,115,006 equity shares held by the Company (which were encumbered): (i) 24,505,435 equity shares (representing 20% of the current issued and paid-up share capital of GLS) were locked-in as promoter's contribution pursuant to the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended; and (ii) 96,09,571 equity shares (representing 7.84% of the current issued and paid-up share capital of GLS) are subject to non-disposal undertaking pursuant to the Share Purchase Agreement, which is valid for the period until the earlier of (a) one year from the closing under the Share Purchase Agreement; and (b) one month from the date of compliance with applicable minimum public shareholding requirements by GLS and Nirma Limited.

Signature of the Authorised Signatory

V.S. Mani

Executive Director & Global Chief Financial Officer

Place: Mumbai

Date: March 13, 2024

